Quarterly report pursuant to Section 13 or 15(d)

Segments

v3.20.2
Segments
9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
SEGMENTS SEGMENTS
We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
  For the three months ended September 30, For the nine months ended September 30,
(In thousands) 2020 2019 2020 2019
Revenue from services:
Pharmaceutical $ —  $ —  $ —  $ — 
Diagnostics 382,498  181,139  804,309  538,488 
Corporate —  —  —  — 
$ 382,498  $ 181,139  $ 804,309  $ 538,488 
Revenue from products:
Pharmaceutical $ 28,702  $ 26,161  $ 89,133  $ 80,143 
Diagnostics —  —  —  — 
Corporate —  —  —  — 
$ 28,702  $ 26,161  $ 89,133  $ 80,143 
Revenue from transfer of intellectual property and other:
Pharmaceutical $ 6,819  $ 20,676  $ 31,057  $ 58,165 
Diagnostics 10,045  —  16,240  — 
Corporate —  796  —  796 
$ 16,864  $ 21,472  $ 47,297  $ 58,961 
Operating income (loss):
Pharmaceutical $ (14,425) $ (14,232) $ (34,546) $ (52,265)
Diagnostics 46,172  (16,363) 68,975  (77,945)
Corporate (9,808) (8,416) (26,071) (31,378)
$ 21,939  $ (39,011) $ 8,358  $ (161,588)
Depreciation and amortization:
Pharmaceutical $ 7,316  $ 7,673  $ 21,556  $ 22,580 
Diagnostics 13,720  16,116  43,739  48,647 
Corporate —  16  —  54 
$ 21,036  $ 23,805  $ 65,295  $ 71,281 
Loss from investment in investees:
Pharmaceutical $ (110) $ (294) $ (433) $ (2,419)
Diagnostics —  —  —  — 
Corporate —  —  —  — 
$ (110) $ (294) $ (433) $ (2,419)
Revenues:
United States $ 400,778  $ 189,485  $ 847,539  $ 558,688 
Ireland 8,988  22,968  37,736  65,675 
Chile 11,062  8,436  33,064  25,352 
Spain 3,713  4,172  12,005  13,466 
Israel 1,119  1,938  4,010  8,822 
Mexico 2,280  1,642  5,987  5,231 
Other 124  131  398  358 
$ 428,064  $ 228,772  $ 940,739  $ 677,592 
(In thousands) September 30,
2020
December 31,
2019
Assets:
Pharmaceutical $ 1,151,065  $ 1,174,639 
Diagnostics 1,176,028  1,035,112 
Corporate 44,198  99,521 
$ 2,371,291  $ 2,309,272 
Goodwill:
Pharmaceutical $ 240,986  $ 237,131 
Diagnostics 434,809  434,809 
Corporate —  — 
$ 675,795  $ 671,940 
No customer represented more than 10% of our total consolidated revenue during the nine months ended September 30, 2020 and 2019. As of September 30, 2020 and December 31, 2019, no customer represented more than 10% of our accounts receivable balance.